Amphastar Pharmaceuticals, Inc. 8-K

What Happened

• Amphastar Pharmaceuticals, Inc. announced its financial results for the three months ended March 31, 2026 in a press release dated May 7, 2026. The company furnished that press release as Exhibit 99.1 to a Current Report on Form 8-K filed the same day. The report was signed by William J. Peters, Chief Financial Officer, Executive Vice President and Treasurer.

Key Details

• Filing date: May 7, 2026 (Form 8-K, Item 2.02: Results of Operations and Financial Condition).
• Period covered: three months ended March 31, 2026 (Q1 2026).
• Disclosure format: results announced via press release (Exhibit 99.1) furnished with the 8-K.
• Administrative note: the furnished press release is not deemed "filed" under Section 18 of the Exchange Act and is not automatically incorporated by reference in other filings.

Why It Matters

• This 8-K notifies investors that Amphastar has publicly released its quarterly financial results; investors should review the Exhibit 99.1 press release for revenue, profit/loss, and any commentary or guidance.
• Because the 8-K furnishes (but does not “file”) the press release, the immediate market-relevant information is in that press release rather than the 8-K text itself.